Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Lancet. 2009 Sep 18;374(9697):1243–1251. doi: 10.1016/S0140-6736(09)61526-9

Table 2.

Lung Cancer Incidence (Annualized %) and Characteristics by Randomization Group

CEE plus MPA Placebo HR1 (95% CI) P-value
N (%) N (%)
Lung cancer Incidence 109 (0.16%) 85 (0.13%) 1.23 (0.92, 1.63) 0.16
 Non-small cell lung cancer (NSCLC) 96 (0.14%) 72 (0.11%) 1.28 (0.94, 1.73) 0.12
 Small cell lung cancer (SCLC) 13 (0.02%) 13 (0.02%) 0.96 (0.44, 2.07) 0.91
Non-small cell lung cancer histology
 Adenocarcinoma 46 (0.07%) 36 (0.06%) 1.23 (0.80, 1.91) 0.35
 Squamous cell 14 (0.02%) 17 (0.03%) 0.78 (0.39, 1.59) 0.50
 Large cell/neuroendocrine 8 (0.01%) 6 (0.01%) 1.34 (0.46, 3.85) 0.59
 Unspecified 28 (0.04%) 13 (0.02%) 2.00 (1.04, 3.87) 0.04
Non-small cell lung cancer stage
 Local 17 (0.03%) 18 (0.03%) 0.91 (0.47, 1.77) 0.78
 Regional 21 (0.03%) 18 (0.03%) 1.12 (0.60, 2.10) 0.72
 Distant metastases 40 (0.06%) 22 (0.03%) 1.71 (1.02, 2.88) 0.04
Non-small cell lung cancer grade
 Well differentiated 8 (0.01%) 6 (0.01%) 1.34 (0.46, 3.86) 0.59
 Moderately differentiated 14 (0.02%) 17 (0.03%) 0.77 (0.38, 1.57) 0.48
 Poorly differentiated 29 (0.04%) 14 (0.02%) 2.01 (1.06, 3.81) 0.03
 Anaplastic 3 (<0.01%) 4 (0.01%) 0.69 (0.15, 3.09) 0.63

Small cell lung cancer characteristics not included given the limited number of total cases.

1

HRs, 95% CIs and p-values are from Cox proportional hazards models stratified according to age, prior lung cancer, and DM trial randomization assignment.